Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Orchid Pharma Ltd has submitted its Annual Secretarial Compliance Report for FY 2025-26, reviewed by S Dhanapal & Associates LLP. The auditors confirmed general compliance with SEBI regulations but flagged three issues from prior periods: delayed intimation of Company Secretary resignation (received warning), delayed shareholder approval for continuation of a Non-Executive Director who attained age 75 (fine of Rs. 44,000 paid to NSE and BSE), and delayed intimation for Investor/Analyst Meet in June 2024 (cautionary letter received). Additionally, the statutory auditor did not conduct limited review of financial information of USA-based subsidiaries whose accounts are consolidated with the parent company, citing that statutory audit is not compulsory for non-publicly traded US companies. All other compliance parameters including Secretarial Standards, website disclosures, director disqualification, related party transactions, and insider trading norms were found satisfactory.
The company has paid a fine of Rs. 44,000 for delayed shareholder approval and received warnings/cautionary letters for other delays. These are minor procedural lapses rather than fundamental governance failures, but investors should note the pattern of delayed regulatory intimations.